ArticleJAMA2004
High-dose statins in acute coronary syndromes: not just lipid levels.
Article in JAMA, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- N-3 fatty acid supplementation to routine statin treatment inhibits platelet function, decreases patients' daytime blood pressure, and improves inflammatory status.European journal of clinical pharmacology · 2012Trial
- Simvastatin as a treatment for pulmonary hypertension trial.American journal of respiratory and critical care medicine · 2010 · on this mapTrial
- Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.Journal of clinical lipidologyTrial
- Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?The open cardiovascular medicine journal · 2018Review
- Atorvastatin inhibits the immediate-early response gene EGR1 and improves the functional profile of CD4+T-lymphocytes in acute coronary syndromes.Oncotarget · 2017Article
- High LDL cholesterol and statin use were independently associated with lower eight-year mortality in a cohort free from terminal illness, cardiovascular disease, and diabetes at baseline.Scandinavian journal of primary health care · 2014Article
- Review
- Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease.Expert opinion on investigational drugs · 2008Review
- Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?Drugs & aging · 2008Review
- Evolution of anticoagulant and antiplatelet therapy: benefits and risks of contemporary pharmacologic agents and their implications for myonecrosis and bleeding in percutaneous coronary intervention.Clinical cardiology · 2007Review
- Review
- Review
- Cholesterol lowering for secondary prevention: what statin dose should we use?Vascular health and risk management · 2007Review
- PROVE-IT proves that lower is better: a contrary view.The Canadian journal of cardiology · 2006Review
- Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter?Vascular health and risk management · 2006Review
- Treatment of multiple-risk patients: using combination therapy to treat beyond LDL lowering.Current hypertension reports · 2005Review
- How aggressive should lipid lowering be among patients with acute coronary syndromes?Current cardiology reports · 2005Review
- Ongoing clinical trials of the pleiotropic effects of statins.Vascular health and risk management · 2005Review
- Amelioration of cisplatin-induced nephrotoxicity by statins.Indian journal of pharmacologyArticle
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Comment on
- Erratum issued
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
15337731What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.